Endothelial growth factor receptor (EGFR), isocitrate dehydrogenase (IDH), tumor protein p53, loss of heterozygosity 10q, platelet-derived growth factor receptor alpha (PDGFRA), and circulating tumor cells acts as prognostic biomarkers where the concentration of these biomarkers act as disease progression or the success of therapy. This evidence concerns the gene IDH2 and neoplasm.